

# Ronjon Chakraverty

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8282865/publications.pdf>

Version: 2024-02-01

76  
papers

5,796  
citations

126907

33  
h-index

91884

69  
g-index

83  
all docs

83  
docs citations

83  
times ranked

7063  
citing authors

#	ARTICLE	IF	CITATIONS
1	Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party. <i>Bone Marrow Transplantation</i> , 2021, 56, 605-613.	2.4	6
2	Graft Versus Leukemia: Current Status and Future Perspectives. <i>Journal of Clinical Oncology</i> , 2021, 39, 361-372.	1.6	11
3	Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2021, 385, 228-238.	27.0	209
4	Natural History of Epstein-Barr Virus Replication and Viral Load Dynamics after Alemtuzumab-Based Allogeneic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 682.e1-682.e12.	1.2	2
5	Graft-versus-host disease: a disorder of tissue regeneration and repair. <i>Blood</i> , 2021, 138, 1657-1665.	1.4	14
6	Predictors of recovery following allogeneic CD34+-selected cell infusion without conditioning to correct poor graft function. <i>Haematologica</i> , 2020, 105, 2639-2646.	3.5	17
7	Graft-versus-host disease reduces lymph node display of tissue-restricted self-antigens and promotes autoimmunity. <i>Journal of Clinical Investigation</i> , 2020, 130, 1896-1911.	8.2	27
8	Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study. <i>Blood</i> , 2020, 136, 22-24.	1.4	24
9	A wave of monocytes is recruited to replenish the long-term Langerhans cell network after immune injury. <i>Science Immunology</i> , 2019, 4, .	11.9	41
10	The Obese Liver Environment Mediates Conversion of NK Cells to a Less Cytotoxic ILC1-Like Phenotype. <i>Frontiers in Immunology</i> , 2019, 10, 2180.	4.8	61
11	A Phase I Study Evaluating the Safety and Persistence of Allorestricted WT1-TCR Gene Modified Autologous T Cells in Patients with High-Risk Myeloid Malignancies Unsuitable for Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 1367-1367.	1.4	5
12	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. <i>Nature Medicine</i> , 2018, 24, 282-291.	30.7	216
13	Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency. <i>Blood</i> , 2018, 131, 917-931.	1.4	68
14	Unraveling the Mechanisms of Cutaneous Graft-Versus-Host Disease. <i>Frontiers in Immunology</i> , 2018, 9, 963.	4.8	30
15	Peripheral tissues reprogram CD8+ T cells for pathogenicity during graft-versus-host disease. <i>JCI Insight</i> , 2018, 3, .	5.0	23
16	Redirection to the bone marrow improves T cell persistence and antitumor functions. <i>Journal of Clinical Investigation</i> , 2018, 128, 2010-2024.	8.2	39
17	Predictors of Response in Patients Receiving CD34-Selected Stem Cell Infusions without Conditioning to Correct Graft Failure Following Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 204-204.	1.4	0
18	Dendritic Cells Cross-Present Immunogenic Lentivector-Encoded Antigen from Transduced Cells to Prime Functional T Cell Immunity. <i>Molecular Therapy</i> , 2017, 25, 504-511.	8.2	8

#	ARTICLE	IF	CITATIONS
19	Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult. <i>Blood</i> , 2017, 130, 1327-1335.	1.4	83
20	Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	512
21	Expression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapy. <i>Haematologica</i> , 2016, 101, 482-490.	3.5	6
22	Depletion of CD11c <sup>+</sup> cells in the CD11c.DTR model drives expansion of unique CD64 <sup>+</sup> Ly6C <sup>+</sup> monocytes that are poised to release TNF $\alpha$ . <i>European Journal of Immunology</i> , 2016, 46, 192-203.	2.9	10
23	Impact of Pretransplantation 18 F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1234-1241.	2.0	26
24	Stem Cell Transplantation. , 2015, , 651-675.		1
25	CMV promotes recipient T-cell immunity following reduced-intensity T-cell-depleted HSCT, significantly modulating chimerism status. <i>Blood</i> , 2015, 125, 731-739.	1.4	32
26	CD8 T Cell Tolerance to a Tumor-Associated Self-Antigen Is Reversed by CD4 T Cells Engineered To Express the Same T Cell Receptor. <i>Journal of Immunology</i> , 2015, 194, 1080-1089.	0.8	19
27	Genetic Regulation of Fate Decisions in Therapeutic T Cells to Enhance Tumor Protection and Memory Formation. <i>Cancer Research</i> , 2015, 75, 2641-2652.	0.9	20
28	G-CSF mobilizes CD34 <sup>+</sup> regulatory monocytes that inhibit graft-versus-host disease. <i>Science Translational Medicine</i> , 2015, 7, 281ra42.	12.4	99
29	OX40- and CD27-Mediated Costimulation Synergizes with Anti-PD-L1 Blockade by Forcing Exhausted CD8 <sup>+</sup> T Cells To Exit Quiescence. <i>Journal of Immunology</i> , 2015, 194, 125-133.	0.8	65
30	A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. <i>Blood</i> , 2014, 124, 1277-1287.	1.4	308
31	An unexpected role for platelets in blocking Th17 differentiation. <i>Journal of Clinical Investigation</i> , 2014, 124, 480-482.	8.2	6
32	CMV-IMPACT: Results of a Randomized Controlled Trial of Immuno-Prophylactic Adoptive Cellular Therapy following Sibling Donor Allogeneic HSCT. <i>Blood</i> , 2014, 124, 1109-1109.	1.4	5
33	Pre-Transplantation FDG-PET Predicts Early but Not Late Survival Outcomes Following Allogeneic Transplantation in Chemo-Sensitive Hodgkin Lymphoma. <i>Blood</i> , 2014, 124, 1225-1225.	1.4	1
34	Cell-intrinsic regulation of murine dendritic cell function and survival by prereceptor amplification of glucocorticoid. <i>Blood</i> , 2013, 122, 3288-3297.	1.4	9
35	Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2013, 160, 640-648.	2.5	33
36	Fondation Rene Touraine Pour La Dermatologie. <i>Experimental Dermatology</i> , 2012, 21, 802-814.	2.9	0

#	ARTICLE	IF	CITATIONS
37	Dendritic cells in tissues: in situ stimulation of immunity and immunopathology. Trends in Immunology, 2012, 33, 8-13.	6.8	18
38	Donor Lymphocyte Infusions Modulate Relapse Risk in Mixed Chimeras and Induce Durable Salvage in Relapsed Patients After T-Cellâ€Depleted Allogeneic Transplantation for Hodgkin's Lymphoma. Journal of Clinical Oncology, 2011, 29, 971-978.	1.6	117
39	Specificity for the tumor-associated self-antigen WT1 drives the development of fully functional memory T cells in the absence of vaccination. Blood, 2011, 117, 6813-6824.	1.4	21
40	Families get mobilized to treat AML. Blood, 2011, 117, 746-748.	1.4	3
41	Langerhans cells regulate cutaneous injury by licensing CD8 effector cells recruited to the skin. Blood, 2011, 117, 7063-7069.	1.4	41
42	Memory lapses in graftâ€versusâ€host disease. European Journal of Immunology, 2011, 41, 2530-2534.	2.9	0
43	Directly Selected Cytomegalovirus-Reactive Donor T Cells Confer Rapid and Safe Systemic Reconstitution of Virus-Specific Immunity Following Stem Cell Transplantation. Clinical Infectious Diseases, 2011, 52, 49-57.	5.8	214
44	Allogeneic Transplantation for Lymphoma. Journal of Clinical Oncology, 2011, 29, 1855-1863.	1.6	41
45	Conventional Dendritic Cells Are Required for the Activation of Helper-Dependent CD8 T Cell Responses to a Model Antigen After Cutaneous Vaccination with Lentiviral Vectors. Journal of Immunology, 2011, 186, 4565-4572.	0.8	32
46	Incidence and Dynamics of Epstein-Barr Virus Reactivation After Alemtuzumab-Based Conditioning for Allogeneic Hematopoietic Stem-Cell Transplantation. Transplantation, 2010, 90, 564-570.	1.0	57
47	Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. Blood, 2010, 116, 3080-3088.	1.4	92
48	Genome gains at chromosome 21q21/22 segment leads to coâ€amplification of Down Syndrome Critical Regions and known oncogenes in a case of donor cellâ€derived acute myeloid leukaemia following allogeneic sex mismatched umbilical cord blood transplantation for chronic myeloid leukaemia. British Journal of Haematology, 2010, 151, 285-288.	2.5	6
49	T-Cellâ€Depleted Reduced-Intensity Transplantation Followed by Donor Leukocyte Infusions to Promote Graft-Versus-Lymphoma Activity Results in Excellent Long-Term Survival in Patients With Multiply Relapsed Follicular Lymphoma. Journal of Clinical Oncology, 2010, 28, 3695-3700.	1.6	134
50	HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning. Blood, 2010, 115, 5147-5153.	1.4	56
51	Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation. Journal of Clinical Investigation, 2010, 120, 3855-3868.	8.2	52
52	Favorable Long-Term Survival After Reduced-Intensity Allogeneic Transplantation for Multiple-Relapse Aggressive Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2009, 27, 426-432.	1.6	152
53	Regulatory Mechanisms in Graft-versus-Host Responses. Biology of Blood and Marrow Transplantation, 2009, 15, 2-6.	2.0	21
54	Phase I Study of High-Stringency CD8 Depletion of Donor Leukocyte Infusions After Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation, 2009, 88, 1312-1318.	1.0	23

#	ARTICLE	IF	CITATIONS
55	High Response Rate to Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Indolent Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 50-58.	2.0	94
56	The Host Environment Regulates the Function of CD8+ Graft-versus-Host-Reactive Effector Cells. <i>Journal of Immunology</i> , 2008, 181, 6820-6828.	0.8	29
57	Peripheral Alloantigen Drives Early Dysfunction and Eventual Exhaustion of CTL Following Delayed Donor Leukocyte Infusions.. <i>Blood</i> , 2008, 112, 2346-2346.	1.4	0
58	T Cell Depletion with Alemtuzumab Is Associated with a High Incidence of EBV Viraemia but Low Risk of PTLD Following Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2008, 112, 1177-1177.	1.4	5
59	The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. <i>Blood</i> , 2007, 110, 9-17.	1.4	150
60	Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions. <i>Blood</i> , 2006, 108, 2106-2113.	1.4	96
61	An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. <i>Journal of Experimental Medicine</i> , 2006, 203, 2021-2031.	8.5	170
62	De-Escalation of the Alemtuzumab Dose Prior to Nonmyeloablative HLA-Identical Sibling Transplantation: Crucial Role of Timing.. <i>Blood</i> , 2006, 108, 2901-2901.	1.4	0
63	Expression of 11 $\beta$ -hydroxysteroid dehydrogenase type 1 permits regulation of glucocorticoid bioavailability by human dendritic cells. <i>Blood</i> , 2005, 106, 2042-2049.	1.4	72
64	Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA $\alpha$ 1-peptide tetramers. <i>Journal of Experimental Medicine</i> , 2005, 202, 379-386.	8.5	466
65	Maturation of human monocyte-derived dendritic cells (MoDCs) in the presence of prostaglandin E2 optimizes CD4 and CD8 T cell-mediated responses to protein antigens: role of PGE2 in chemokine and cytokine expression by MoDCs. <i>International Immunology</i> , 2005, 17, 1561-1572.	4.0	38
66	Vitamin D and barrier function: a novel role for extra-renal 1 $\alpha$ -hydroxylase. <i>Molecular and Cellular Endocrinology</i> , 2004, 215, 31-38.	3.2	190
67	Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25 <sup>high</sup> regulatory T cells. <i>Blood</i> , 2004, 103, 2410-2416.	1.4	196
68	Proliferation, Expansion, Effector Differentiation and Survival of GVH-Reactive T Cells Following Delayed DLI to Mixed Chimeras.. <i>Blood</i> , 2004, 104, 594-594.	1.4	1
69	Sequential Blockade and Engagement of Co-Stimulatory Pathways: A Potential Strategy for Amplifying Graft-Versus-Leukemia Responses without GVHD.. <i>Blood</i> , 2004, 104, 3075-3075.	1.4	0
70	Host Environment Dictates the Outcome Following Transfer of Graft-Versus-Host Reactive Effector/Memory T Cells.. <i>Blood</i> , 2004, 104, 3046-3046.	1.4	7
71	Differential Regulation of Vitamin D Receptor and Its Ligand in Human Monocyte-Derived Dendritic Cells. <i>Journal of Immunology</i> , 2003, 170, 5382-5390.	0.8	407
72	Origin and subset distribution of peripheral blood dendritic cells in patients with chronic graft-versus-host disease <sup>1</sup> . <i>Transplantation</i> , 2003, 75, 221-225.	1.0	49

#	ARTICLE	IF	CITATIONS
73	Role of Dendritic Cells in Graft-Versus-Host Disease. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 601-616.	1.8	14
74	High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood, 2002, 99, 4357-4363.	1.4	349
75	Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood, 2002, 99, 1071-1078.	1.4	333
76	Stem Cell Transplantation. , 0, , 419-435.		4